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Background: It was reported that antiretroviral drugs such as efavirenz can increase the catabolism of vitamin D in HIV
infected individuals. We have not found any study that evaluated effects of vitamin D supplementation on the bone
specific biomarkers in HIV positive patients under treatment with antiretroviral regimen containing efavirenz.
Findings: Vitamin D deficiency was detected in 88.4 % of included patients. Baseline osteocalcin, but not collagen
telopeptidase, serum levels were lower than normal range in all of these individuals. Both bone biomarkers’
concentrations increased significantly (p< 0.001 for both of them) after supplementation of vitamin D and it was more
predominant for osteocalcin.
Conclusion: In the HIV-infected patients under treatment with efavirenz, vitamin D deficiency is prevalent. After
supplementation with single dose of 300,000 IU vitamin D in this population, the activation of osteoblasts and osteoclasts
stimulates bone formation and resorption respectively with favorable bone formation without any adverse event.
Significant percent of HIV infected individuals are vitamin d deficient that could benefit from vitamin D supplementation.
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Background
Human immunodeciency virus (HIV) infection is a glo-
bal health care problem and about 33 millions indivi-
duals living with this infection around the world [1].
Following screening program and early diagnosis of HIV
infection, introducing of effective antiretroviral therapy
and improvement of patient’ care; survival increased and
consequently chronic diseases such as bone disorders
diagnosed more frequently in this population [2]. Studies
have shown that bone disorders are more prevalent in
HIV positive patients in comparison with HIV negative
individuals who were at the same age range, sex and race
[3-8]. Associations between bone mineral density decline
and duration of HIV infection, HIV viral load and CD4
cells count was reported [9].* Correspondence: khalilih@tums.ac.ir
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and reproduction in any medium, provided theHIV infected individuals are more vulnerable to micro-
elements malnutrition due to decreased intake, mal-
absorption, increased need, metabolism changes and
antiretroviral therapy. Vitamin D deficiency, as a fun-
damental element for regulation of bone metabolism,
was reported more frequently in this population [2].
Also it was reported that antiretroviral drugs such as
efavirenz can increase the catabolism of vitamin D in
HIV infected individuals [10]. Recently efavirenz was
proposed as a risk factor for vitamin D deficiency in
this population [10-12]. We have not found any inter-
ventional study that showed the effects of vitamin D
supplementation on the bone specific biomarkers in HIV
positive patients under treatment with antiretroviral regi-
men including efavirenz. In present study we have evalu-
ated the effects of vitamin D supplementation on bone
specific biomarkers including osteocalcin (OC); an osteo-
blast metabolic marker and collagen telopeptidase (CTx); a
bone collagen degradation byproduct as indicator of bone
resorption [7] in vitamin D deficient HIV positive indivi-
duals under treatment with antiretroviral drugs including
efavirenz.ed Central Ltd. This is an Open Access article distributed under the terms of the
reativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution,
original work is properly cited.
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From 121 HIV positive individuals that had the study in-
clusion criteria, 107 of them had vitamin D deficiency
(88.4 %) and included in intervention phase of the study.
From included individuals, 98 of them (74 male and 24
female with mean± SD ages of 40.25 ± 8.94 years old)
completed the study. Nine patients excluded from the
study due to follow-up problems. The median period
past from the patients’ efavirenz starting date up to enter
the study was 15.5 months with a range of 1–49 months.
The patients’ demographic and clinical data have been
shown in the Table 1.
The patients’ vitamin D and bone biomarkers’ levels
at baseline and after three months of vitamin D admin-
istration were shown in the Table 2. Baseline OC levels
were lower than normal range (5–25 ng/ml) in all of
the HIV infected individuals whereas CTx levels were in
the normal range (0.11-0.75 ng/ml) for included
patients. Both bone biomarkers’ concentrations increased
significantly after supplementation of vitamin D but
these changes was not equal. OC concentration raisedTable 1 The demographic, baseline clinical characteristics
of the patients





Age, mean(SD), years 40.26 ± 8.99
Injection drug abuse, number (percent)
Yes 55(56.1)
No 43(43.9)
Duration since HIV diagnosis, median (range),
month
26.5 (3–152)
Chronic hepatitis B, number (percent)
Yes 6(6.1)
No 92(93.9)
Chronic hepatitis C, number (percent)
Yes 53(54.1)
No 45(45.9)
GFR, mL/min/1.73 m2, number (percent)
≥90 75(76.6)
<90 23(23.4)
Calcium level mg/dl, mean (SD) 8.97 ± 0.40
Phosphorus level mg/dl, mean (SD) 3.25 ± 0.69
Parathyroid hormone level pg/ml, mean (SD) 33.92 ± 17.96
Alkaline phosphatase IU/l, mean (SD) 200.80 ± 72.05
Antiretroviral regimen, number (percent)
Standard (Zidovudine + lamivudine + Efavirenz) 88(89.7)
Other 10(10.3)
GFR: Glomerular filtration rate.208 percent while CTx increased about 60 percent above
baseline values.
Serum OC levels had positive correlations with vitamin
D serum level (r = 0.38, p< 0.001), serum alkaline phos-
phatase (r = 0.38, p< 0.001), CTx concentration (r = 0.47,
p< 0.001) and serum Phosphor level (ALK) (r = 0.25,
p= 0.013). Also OC serum level was significantly lower
in HIV/HCV (hepatitis C virus) co-infected patients than
HCV negative individuals (p= 0.03).
Patients’ serum levels of CTx had statistically signifi-
cant inverse correlations with glomerular filtration rate
(GFR) (r =−.025, p= 0.02). Conversely, CTx levels had
positive associations with serum levels of ALP (r = 0.35,
p< 0.001), serum P concentration (r = 0.21, p=0.04), serum
OC level (r = 0.73, p< 0.001) and serum vitamin D concen-
tration (r = 0.296, p=0.01).
We have not found any significant correlation between
duration of efavirenz therapy and serum level of vitamin
D or bone biomarkers’ levels.
Discussion
Considering high prevalence of vitamin D deficiency in
HIV infected individuals, this population can benefits from
vitamin D nutritional support. These patients usually have
complex drug therapy regimen including antiretroviral
drugs and prophylactic therapies for opportunistic infec-
tions. With respect to importance of treatment compliance
in this group of patients, single dose supplementation may
be preferred. This is the first interventional study that has
evaluated the effects of single dose of vitamin D3 on the
bone specific biomarkers in this population.
Bone specific markers are helpful biochemical indices to
evaluate bone dynamic and metabolic status [7]. Effects of
HIV infection and antiretroviral therapy on bone biomar-
kers in HIV positive individuals were reported [13-15].
Changes in the bone biomarkers reach to steady state ap-
proximately 3 months after exposure to conditions or
drugs that affect the bone turn over metabolism [13,16].
We have measured the bone biomarkers at baseline and
three months after vitamin D supplementation.
The patients’ median of vitamin D baseline serum levels
were in moderate deficiency range. After three months of
vitamin D supplementation, it elevated to normal level
range that was far from toxic levels [17]. This intervention
was effective, safe and convenient like other populations
[18-20].
In this study, changes in the bone specific biomarkers’
concentrations clearly indicated that the single high dose of
vitamin D3 can increase bone metabolic function and osteo-
blasts activity and bone formation were more enhanced.
Osteoblast and osteoclast cells activity are correlate to
each other via osteoprotegrin (OPG)/receptor activator of
nuclear factor-kappa B (RANK)/RANK ligand (RANKL)
system [21,22]. Recent studies confirmed existence of






Serum 25-OH vitamin D (nmol/L) 18.54 ± 12.92 96.10 ± 37.05 <0.001
PTH (pg/ml) 33.92 ± 17.96 22.53 ± 18.69 <0.001
Serum ALP (IU/L) 200.80 ± 72.05 273.52 ± 96.55 <0.001
Serum Osteocalcin (ng/ml) 3.60 ± 3.76 11.09 ± 7.32 <0.001*
Serum CTx (ng/ml) 0.48 ± 0.25 0.77 ± 0.40 <0.001
ALP: Alkaline Phosphatase; CTx:Collagen Type 1 C-Telopeptide; PTH: Parathyroid Hormone.
* Sign test was used to evaluate the difference between pre and post intervention values.
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clasts surface [23,24]. This vitamin can improve osteoblats
activity, osteocalcin concentration and bone formation.
Also it can increase bone resorption following increase in
RANKL expression [25]. This remove and repair (remodel-
ing process) is necessary for keeping skeletal strength and
its architectures as well as repair the micro fractures and
regulate calcium serum level [8].
HIV infected individuals’ bone health has been described
in previous studies [2,3,9,14]. In vitro studies confirmed
that HIV virus's antigens like gp120 and p55-gag can in-
duce osteoblasts apoptosis and RANKL expression, result-
ing in increase bone resorption. Additionally antiretroviral
drugs also can affect the bone [15]. Our data showed that
osteocalcin as a bone formation biomarker is lower than
desirable concentration in these patients and had positive
correlation with vitamin D serum level. This finding is in
agreement with the previous studies [14,26].
Following vitamin D supplementation in our patients,
osteocalcin serum concentration increased about three fold
compared with its baseline value but serum CTx concen-
tration rose to a lesser extent. Increasing in concentration
of bone formation marker followed by increasing in bone
resorption marker level known as overall remodeling
process activation that have positive balance on the bone
formation. These results are in consistence with previous
reports with triparetide, showed that activation of bone re-
modeling can result in new bone formation [27,28].
There are several limitations to our study. An important
one is the lack of bone mineral density assessment in our
patients. We did not detect any significant correlation be-
tween biochemical or bone markers with length of efavir-
enz therapy and it may be due to limited sample size of the
study. Our study had not enough duration of follow-up to
evaluate effect of vitamin D on bone fracture reduction.
Conclusion
In conclusion our data suggests that in HIV-infected
individuals under treatment with efavirenz, vitamin D
deficiency is prevalent and consequently bone health
may be affected. After supplementation with single dose
of 300,000 IU vitamin D, the activation of osteoblasts
and osteoclasts stimulates bone formation and resorptionrespectively with favorable bone formation without any
adverse event.
Method
This prospective interventional study was done in HIV
Clinic of Iranian HIV/AIDS Research Center affiliated to
Tehran University of Medical Sciences; the major referral
center for HIV infected patients’ care in Tehran, Iran.
HIV infected individuals aged 18 to 65 years old included
in this study if they were under treatment with antiretro-
viral drugs including efavirenz 600 mg daily for at least
one month. The Tehran University of Medical Sciences
local ethical committee approved the study and all subjects
entered in the assessment after giving written informed
consent. We excluded individuals with known risk factors
that could affect the bone turnover including history of
hypogonadism, menopause, abnormal renal, hepatic or
thyroid function tests, adrenal insufficiency, metabolic
bone diseases, pregnancy and lactation, malignancy, im-
mobility for more than one-week, and taking medications
known to influence calcium or vitamin D metabolism or
bone mass such as corticosteroids, thiazides, diuretics,
anabolic steroids, and anticonvulsants. We also excluded
subjects with a history of any vitamin D supplement intake
during previous 3 months.
Demographic data of the patients were collected and
following an overnight fasting, 10 ml venous blood sam-
ple were obtained and then serum was separated and
froze at −70°C until time of analysis.
Patients’ serum levels of calcium (Ca), P, creatinine (Cr)
and total ALP and albumin (Alb) were measured using
standard automated equipment. Total serum concentration
of Ca was corrected based on serum albumin according
to; corrected total Ca (mg/ dl) =measured Ca (mg/dl) +
0.8 × [4−Alb (g/dl)]. Patients’ GFR was calculated based
on Cockroft-Gault formula. The serum PTH (Biomerica,
Germany), OC (DIAsource, Belgium), CTx and vitamin D
(25-OH vitamin D) (Immuno-diagnostic systems, United
Kingdom) concentrations were measured using enzyme-
linked immunosorbent assay kits.
For vitamin D deficient patients (serum vitamin D con-
centration less than 35 nmol/ml) 300,000 units vitamin D
was administered intramuscularly. All included patients
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mentioned laboratory parameters were repeated at this
time.
Data were analyzed using SPSS 16.0 software (SPSS,
Chicago, IL, USA). Kolmogorov-Smirnov test was used
to determine the normal frequency of different variables.
Results were expressed as mean ± SD for parametric and
median (range) for nonparametric data. Pearson and
Spearman correlation coefficients were used to analyze
the correlations, and paired t tests or Sign tests were
used for comparing data before and after intervention. A
p-value of less than 0.05 was considered statistically sig-
nificant for all analyses.
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